Dizhe Medicine (688192.SH) latest research progress on multiple blood tumors was selected for presentation at the annual meeting of the European Hematology Association and the International Conference on Malignant Lymphoma.

DiZh Medicine (688192.SH) announced that the company will present the latest clinical data of 8 studies in its hematologic oncology pipeline at two major international academic conferences in the field of hematology to be held in June this year the 2025 European Hematology Association (EHA) Annual Congress and the 18th International Conference on Malignant Lymphoma (ICML). The company's core products, GYRZ (generic name: Golixetini capsule) and DZD8586, have made progress in lymphoma research and have received three oral presentations since this year's American Society of Clinical Oncology (ASCO) Annual Meeting. The latest 2-year follow-up data of the phase II prospective multicenter clinical study JACKPOT26 of GYRZ has been selected for presentation at the EHA Congress and also received an oral presentation at the ICML Congress. The study aims to evaluate the safety and efficacy of GYRZ for maintenance therapy in patients with peripheral T-cell lymphoma (PTCL) who have achieved remission after first-line systemic treatment. The results show that GYRZ can effectively maintain treatment efficacy and deepen tumor remission in PTCL patients after first-line treatment, with manageable safety. In the field of B-cell non-Hodgkin lymphoma (B-NHL) treatment, two studies of DZD8586 have been successively selected for presentation at the ASCO, EHA, and ICML international academic conferences. One study, a pooled analysis of a phase I/II clinical study of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously received covalent or non-covalent bruton tyrosine kinase (BTK) inhibitors and BTK degraders, received oral presentations at ASCO and ICML. The study demonstrated that DZD8586 exhibited significant anti-tumor activity in heavily treated CLL/SLL patients, with good tolerability and manageable safety.